Stock Events

Stock Events

Celcuity 

$109.91
36
-$3.60-3.17% 13:45 Today

Statistics

Day High
113.66
Day Low
109.71
52W High
144.98
52W Low
13.34
Volume
86,921
Avg. Volume
-
Mkt Cap
5.36B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

6AugExpected
Q2 2024
Q3 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Next
-1.11
-0.94
-0.78
-0.62
Expected EPS
-1.106364
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-177.04MNet Income

Analyst Ratings

155.57Average Price Target
The highest estimate is 171.00.
From 7 ratings within the last 6 months. This is not an investment recommendation.
Buy
86%
Hold
14%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CELC. It's not an investment recommendation.
Microsoft
11
MSFT
Amazon
10
AMZN
NVIDIA
10
NVDA
Apple
8
AAPL

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Guardant Health
GH
Mkt Cap22.27B
Guardant Health operates in the liquid biopsy and cancer diagnostics sector, directly competing with Celcuity's technology for detecting and analyzing cancer.
Fulgent Genetics
FLGT
Mkt Cap592.15M
Fulgent Genetics provides comprehensive genetic testing solutions, competing with Celcuity in the precision medicine and diagnostics field.
Bionano Genomics
BNGO
Mkt Cap13.2M
Bionano Genomics competes in the genomic analysis space, offering platforms that could rival Celcuity's cellular analysis technologies.
Pacific Biosciences of California
PACB
Mkt Cap521.81M
Pacific Biosciences of California offers sequencing systems that compete in the genomics and diagnostics market, relevant to Celcuity's operations.
Illumina
ILMN
Mkt Cap28.55B
Illumina provides sequencing and array-based solutions for genetic analysis, competing with Celcuity in the genomics and diagnostics market.
Qiagen NV
QGEN
Mkt Cap8.07B
Qiagen N.V. offers sample to insight solutions that compete with Celcuity in the field of molecular diagnostics and research.
CRISPR Therapeutics
CRSP
Mkt Cap5.92B
CRISPR Therapeutics is involved in gene editing, a technology that could compete with Celcuity's cellular analysis in developing treatments.
Intellia Therapeutics
NTLA
Mkt Cap2.45B
Intellia Therapeutics is engaged in CRISPR/Cas9 technology, presenting potential competition in the development of genomic and cellular therapies.

About

Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.
Show more...
CEO
Mr. Brian F. Sullivan
Employees
155
Country
United States
ISIN
US15102K1007

Listings

F
DE
7VR.F
XETRA
DE
7VR.XETRA
MU
DE
7VR.MU
XNAS
US
CELC

0 Comments

Share your thoughts

FAQ

What is Celcuity stock price today?▼
The current price of CELC is $109.91 USD — it has decreased by -3.17% in the past 24 hours. Watch Celcuity stock price performance more closely on the chart.
What is Celcuity stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Celcuity stocks are traded under the ticker CELC.
Is Celcuity stock price growing?▼
CELC stock has risen by +2.13% compared to the previous week, the month change is a +24.94% rise, over the last year Celcuity has showed a +709.47% increase.
What is Celcuity market cap?▼
Today Celcuity has the market capitalization of 5.36B
When is the next Celcuity earnings date?▼
Celcuity is going to release the next earnings report on August 06, 2026.
What were Celcuity earnings last quarter?▼
CELC earnings for the last quarter are -0.97 USD per share, whereas the estimation was -1.04 USD resulting in a +6.73% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Celcuity revenue for the last year?▼
Celcuity revenue for the last year amounts to 0 USD.
What is Celcuity net income for the last year?▼
CELC net income for the last year is -177.04M USD.
How many employees does Celcuity have?▼
As of July 10, 2026, the company has 155 employees.
In which sector is Celcuity located?▼
Celcuity operates in the Health & Wellness sector.
When did Celcuity complete a stock split?▼
Celcuity has not had any recent stock splits.
Where is Celcuity headquartered?▼
Celcuity is headquartered in Minneapolis, United States.